Fifteen of 23 pathologically confirmed cases of multiple system atrophy (MSA) showed some initial response to levodopa and eight of these remained at least partially responsive at the time of death. Eleven developed motor oscillations, and drug-induced dyskinesias, often involving the face and jaw, were also seen in 11 cases. Acute levodopa and apomorphine challenges were administered to 11 patients with clinical MSA who were considered levodopa responsive. A short duration relatively small amplitude response with associated dyskinesias occurred in six and a further three developed dyskinesias without any motor response. Following levodopa withdrawal, a delayed deterioration occurred after three to six days in six patients, five of whom had shown no short duration motor response to the acute challenges. The occurrence of levodopa-induced dyskinesias without a concomitant motor response and delayed deterioration several days after levodopa withdrawal may be more typical of patients with MSA than Parkinson's disease.
To assess these issues further we studied the motor response to single challenges of levodopa and apomorphine, or to the withdrawal of levodopa, in 11 patients with clinical MSA who showed some previous dopaminergic response. We also reviewed the levodopa response in 23 cases of histologically proven MSA from the United Kingdom Parkinson's Disease Society brain bank (PDSBB).
Patients and Methods
Clinical studies Eleven patients (7 female, 4 male) with clinical features suggestive of MSA who on review of their case notes had an unequivocal history of levodopa responsiveness were selected for study. The mean age of onset of symptoms was 55 years (39-67) and the mean disease duration 8 years (4) (5) (6) (7) (8) (9) (10) (11) (12) Patients who showed no motor response to the acute dopaminergic challenges or who were not disabled after 12 hours without levodopa, despite having shown a short duration response, were withdrawn from all levodopa and followed for later deterioration. As soon as patients demonstrated further motor decline, so that they were not unacceptably disabled or distressed, they were restarted on levodopa and the timing of subsequent improvement noted, according to measurements of motor performance performed each 3 hours during daylight hours.
Pathologically proven cases The case histories of 23 cases with histologically proven MSA collected over a 5 year period at the PDSBB were reviewed. Halfbrains fixed in 10% neutral formalin were available for examination using standard neuropathological methods. 
Results

Clinical studies
Of the 11 patients studied the initial motor response with levodopa was classified as moderate in seven and good in four. Ten had developed dyskinesias thought to be levodopa induced; in 6 these were predominantly choreic in nature, in 3 they were dystonic while in one they appeared more myoclonic. Dyski-nesias began a mean of 2s5 years after levodopa introduction, were generalised including the facial musculature in 7 cases, involved only one limb in 2 and were isolated to the face in one. Six patients described motor fluctuations.
Following the acute challenge of levodopa six patients had a definite motor response, in all associated with dyskinesias. Five of these had described motor fluctuations. After acute testing, five patients without a short term motor response and two with an acceptable level of mobility after 12 hours without treatment, despite having a short term response, were withdrawn from levodopa. All seven patients subsequently deteriorated; one who also had a short duration motor response, deteriorated to an unacceptable level after 24 hours, while three patients took three days, and three took five to six days to show decline. In five cases deterioration included gradual decline in bulbar function, with progressive dysphonia, difficulty with mastication and dysphagia. Three patients became almost completely aphonic and aphagic. With the reintroduction of levodopa six responded with a return to approximately their previous level of motor performance over 24 hours, three within 12 hours, while one took several days. The figure shows sample responses from two patients; one with a short duration motor response accompanied by dyskinesias who did not have a prolonged period of levodopa withdrawal, and another from a patient with dyskinesias without a short duration motor response following the levodopa challenge, who deteriorated over several days without levodopa.
Pathologically proven cases
The mean age of disease onset was 57a 1 years (34-76), mean disease duration 6-8 years (2-11) and mean age at death 63-9 years (39-80); 14 patients were female and nine were male. An akinetic/rigid onset was most common and occurred in isolation in 14 patients, and with some associated tremor in a further five. Within 1 year of disease onset seven cases developed autonomic features, nine suffered from falls, three had pyramidal tract signs and one had cerebellar features. The initial diagnosis was PD in 17, MSA in four and two were labelled as atypical Parkinsonism.
An did not assess the levodopa response in all cases of MSA we were able to locate and confirm a response in 11 of 30 patients whose case notes were reviewed. The criteria we have used for the clinical diagnosis are stringent, but as the final diagnosis of MSA is a pathological one, we acknowledge that some of our cases may turn out to have either PD or another Parkinsonian syndrome. Among our cases of pathologically proven MSA some initial levodopa response was recorded in about 70% although ony a third were felt to still have some response at death. If we consider only a response of > than 50% to be significant then only 9/21 responded initially with 6/21 still responsive at death.
We have observed three types of levodopa response in clinical MSA. Firstly, a short duration motor improvement with associated "on" period dyskinesias, similar to that seen in many patients with Parkinson's disease treated with levodopa for several years. Although some patients with PD can have a similar magnitude of response to our cases, it was our impression that the magnitude was smaller and of less functional benefit than is usual in PD. However, the small number of patients involved did not allow a meaningful statistical comparison. A finding rarely seen in PD was the development of levodopa-induced dyskinesias in the absence of a demonstrable short duration motor response. In all of these cases, however, there was an undoubted delayed deterioration on cessation of treatment. Finally, a delayed deterioration of motor status over several days following withdrawal of levodopa occurred in some cases without an observable short term response of any sort. This deterioration often included profound disturbance of bulbar function. In these patients there was a more rapid restoration of motor performance following reintroduction of levodopa.
Levodopa-induced dyskinesias, at least initially restricted to the face and jaw, are well described in MSA 11 [16] [17] [18] [19] and rare cases with facial dyskinesia without therapeutic improvements have also been reported.20 In our study we have also found facial dyskinesias to be common, although usually occurring in combination with more generalised dyskinesias. The development of dyskinesias in the absence of a short duration motor response is unusual in PD, and was found in only three of 24 patients studied by Muenter and Rapid improvement in motor performance after reintroduction of levodopa was commonly reported in the era of levodopa drug holidays. 27 In fact an increased response, with considerable reduction in the pre-withdrawal level of disability, has also been reported. 27 We did not observe an enhanced response to levodopa following reintroduction in our patients, but the rapidity of response suggests a disassociation between rate of deterioration following cessation of treatment and the speed of motor improvement on reintroduction of levodopa.
Our observations have confirmed previous studies suggesting that a response to levodopa with the later development of motor fluctuatiQns and levodopa-induced dyskinesias is not specific to patients with Lewy body pathology.3 [28] [29] [30] We also conclude that in MSA a response to levodopa occurs more often than is generally believed, depending on duration and stage of illness, although the magnitude and nature of the response can differ from that usually seen in Parkinson's disease.
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